Automated Author Profile

Qin, Xia

Current S-Index

4.3

Sum of Dataset Indices for all datasets

Average Dataset Index per Dataset

0.6

Average Dataset Index per dataset

Total Datasets

7

Total datasets for this author

Average FAIR Score

69.8%

Average FAIR Score per dataset

Total Citations

5

Total citations to the author's datasets

Total Mentions

0

Total mentions of the author's datasets

S-Index Interpretation

S-Index Over Time

Cumulative Citations Over Time

Cumulative Mentions Over Time

Datasets

Recommendations for the selection of nucleoside analogues as antihuman herpesvirus drugs: a real-world analysis of reported cases from the FDA adverse event reporting system

The aim of this study is to provide guidance for refining medication protocols, developing alternative strategies, and enhancing protection against herpesvirus infections in personalized clinical settings. Adverse drug events (ADEs) data for anti-herpesvirus from the first quarter of 2004 to the fourth quarter of 2022 were collected from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis was performed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) methods for data mining. A total of 18,591, 24,206, 6,150, and 419 reports of ADEs associated with acyclovir (ACV), valacyclovir (VACV), ganciclovir (GCV), and famciclovir (FCV) were screened and extracted from the FAERS. In this study, the report summarized the high frequency and strong correlation of ADEs for the four drugs at the Preferred Term (PT) level. Additionally, the analysis also identified the relationship between ADEs and factors such as age, gender, and severity of outcome at the System Organ Class (SOC) level. The safety reports for the four-nucleoside analogue anti-herpesvirus drugs are diverse and interconnected. Dosing for patients with herpesvirus infections should be tailored to their specific conditions and the potential risk of disease.

Authors

  • Gao, Caixia ;
  • Dong, Xiaomei ;
  • Zhang, Jun ;
  • Mao, Lejiao ;
  • Guo, Changxin ;
  • Qin, Xia ;
  • Zou, Zhen
1 Citation0 Mentions85% FAIR0.7 Dataset Index
10.6084/m9.figshare.261309102024

Recommendations for the selection of nucleoside analogues as antihuman herpesvirus drugs: a real-world analysis of reported cases from the FDA adverse event reporting system

The aim of this study is to provide guidance for refining medication protocols, developing alternative strategies, and enhancing protection against herpesvirus infections in personalized clinical settings. Adverse drug events (ADEs) data for anti-herpesvirus from the first quarter of 2004 to the fourth quarter of 2022 were collected from the FDA Adverse Event Reporting System (FAERS). Disproportionality analysis was performed using Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) methods for data mining. A total of 18,591, 24,206, 6,150, and 419 reports of ADEs associated with acyclovir (ACV), valacyclovir (VACV), ganciclovir (GCV), and famciclovir (FCV) were screened and extracted from the FAERS. In this study, the report summarized the high frequency and strong correlation of ADEs for the four drugs at the Preferred Term (PT) level. Additionally, the analysis also identified the relationship between ADEs and factors such as age, gender, and severity of outcome at the System Organ Class (SOC) level. The safety reports for the four-nucleoside analogue anti-herpesvirus drugs are diverse and interconnected. Dosing for patients with herpesvirus infections should be tailored to their specific conditions and the potential risk of disease.

Authors

  • Gao, Caixia ;
  • Dong, Xiaomei ;
  • Zhang, Jun ;
  • Mao, Lejiao ;
  • Guo, Changxin ;
  • Qin, Xia ;
  • Zou, Zhen
1 Citation0 Mentions85% FAIR0.7 Dataset Index
10.6084/m9.figshare.26130910.v12024

Autophagy-dependent release of zinc ions is critical for acute lung injury triggered by zinc oxide nanoparticles

Pulmonary exposure to zinc oxide nanoparticles (ZnONPs) could cause acute lung injury (ALI), but the underlying molecular mechanism remains unclear. Herein, we established a ZnONPs-induced ALI mouse model, characterized by the histopathological changes (edema and infiltration of inflammatory cells in lung tissues), and the elevation of total protein and cytokine interleukin-6 in bronchoalveolar lavage fluid in time- and dose-dependent manners. This model also exhibited features like the disturbance of redox-state (reduced of glutathione to glutathione disulfide ratio, elevation of heme oxygenase-1 and superoxide dismutase 2), the decrease of adenosine triphosphate synthesis and the release of zinc ions in the lung tissues. Interestingly, we found that ZnONPs exposure caused the accumulation of autophagic vacuoles and the elevation of microtubule-associated proteins 1A/1B light chain (LC)3B-II and p62, indicating the impairment of autophagic flux. Our data indicated that the above process might be regulated by the activation of AMP-activated protein kinase but not the mammalian target of rapamycin pathway. The association between ZnONPs-induced ALI and autophagy was further verified by a classical autophagy inhibitor, 3-methyladenine (3-MA). 3-MA administration reduced the accumulation of autophagic vacuoles, the expression of LC3B-II and p62, followed by a significant attenuation of histopathological changes, inflammation, and oxidative stress. More importantly, 3-MA could directly decrease the release of zinc ions in lung tissues. Taken together, our study provides the evidence that ZnONPs-induced pulmonary toxicity is autophagy-dependent, suggests that limiting the release of zinc ions by inhibiting autophagy could be a feasible strategy for the prevention of ZnONPs-associated pulmonary toxicity.

Authors

  • Jiang, Xuejun ;
  • Tang, Qianghu ;
  • Zhang, Jun ;
  • Wang, Hong ;
  • Bai, Lulu ;
  • Meng, Pan ;
  • Qin, Xia ;
  • Xu, Ge ;
  • Bose, Diptiman D. ;
  • Wang, Bin ;
  • Chen, Chengzhi ;
  • Zou, Zhen
0 Citations0 Mentions85% FAIR0.5 Dataset Index
10.6084/m9.figshare.77313142019

Autophagy-dependent release of zinc ions is critical for acute lung injury triggered by zinc oxide nanoparticles

Pulmonary exposure to zinc oxide nanoparticles (ZnONPs) could cause acute lung injury (ALI), but the underlying molecular mechanism remains unclear. Herein, we established a ZnONPs-induced ALI mouse model, characterized by the histopathological changes (edema and infiltration of inflammatory cells in lung tissues), and the elevation of total protein and cytokine interleukin-6 in bronchoalveolar lavage fluid in time- and dose-dependent manners. This model also exhibited features like the disturbance of redox-state (reduced of glutathione to glutathione disulfide ratio, elevation of heme oxygenase-1 and superoxide dismutase 2), the decrease of adenosine triphosphate synthesis and the release of zinc ions in the lung tissues. Interestingly, we found that ZnONPs exposure caused the accumulation of autophagic vacuoles and the elevation of microtubule-associated proteins 1A/1B light chain (LC)3B-II and p62, indicating the impairment of autophagic flux. Our data indicated that the above process might be regulated by the activation of AMP-activated protein kinase but not the mammalian target of rapamycin pathway. The association between ZnONPs-induced ALI and autophagy was further verified by a classical autophagy inhibitor, 3-methyladenine (3-MA). 3-MA administration reduced the accumulation of autophagic vacuoles, the expression of LC3B-II and p62, followed by a significant attenuation of histopathological changes, inflammation, and oxidative stress. More importantly, 3-MA could directly decrease the release of zinc ions in lung tissues. Taken together, our study provides the evidence that ZnONPs-induced pulmonary toxicity is autophagy-dependent, suggests that limiting the release of zinc ions by inhibiting autophagy could be a feasible strategy for the prevention of ZnONPs-associated pulmonary toxicity.

Authors

  • Jiang, Xuejun ;
  • Tang, Qianghu ;
  • Zhang, Jun ;
  • Wang, Hong ;
  • Bai, Lulu ;
  • Meng, Pan ;
  • Qin, Xia ;
  • Xu, Ge ;
  • Bose, Diptiman D. ;
  • Wang, Bin ;
  • Chen, Chengzhi ;
  • Zou, Zhen
0 Citations0 Mentions85% FAIR0.4 Dataset Index
10.6084/m9.figshare.7731314.v12019

CCDC 953842: Experimental Crystal Structure Determination

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

Authors

  • Qin, Xia ;
  • Fan, Zhen ;
  • Xu, Yao Yao ;
  • Ding, Bin ;
  • Wang, Ying ;
  • Wang, XiuGuang
1 Citation0 Mentions50% FAIR0.7 Dataset Index
10.5517/cc110k3q2014

CCDC 953843: Experimental Crystal Structure Determination

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

Authors

  • Qin, Xia ;
  • Fan, Zhen ;
  • Xu, Yao Yao ;
  • Ding, Bin ;
  • Wang, Ying ;
  • Wang, XiuGuang
1 Citation0 Mentions50% FAIR0.7 Dataset Index
10.5517/cc110k4r2014

CCDC 604950: Experimental Crystal Structure Determination

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.

Authors

  • Xu, Hai-Yun ;
  • Qin, Xia ;
  • Li, Yi-Zhi ;
  • Ono, N. ;
  • Shen, Zhen
1 Citation0 Mentions50% FAIR0.7 Dataset Index
10.5517/ccn9hjy2006